AstraZeneca Reports Label Update with Positive Cardiovascular Outcomes and Renal Data for Forxiga (dapagliflozin) in EU

 AstraZeneca Reports Label Update with Positive Cardiovascular Outcomes and Renal Data for Forxiga (dapagliflozin) in EU

Shots:

  • The EC has approved label update which is based on Phase III DECLARE-TIMI 58 study results assessing Forxiga vs PBO on CV outcomes in 17,000 patients with T2D at risk of CV events across 33 countries
  • The P-III DECLARE-TIMI 58 study results: reduction in hospitalization for heart failure/CV deaths, safe and effective with no imbalance in amputations, fractures, bladder cancer or Fournier’s gangrene. The inclusion of these results is under regulatory review in the US & China
  • Forxiga (PO, qd) is an SGLT2 inhibitor indicated as monothx. as well as combination therapy to improve glycaemic control with weight loss and blood-pressure reduction as an adjunct to diet and exercise in patients with T2D

Click here to­ read full press release/ article | Ref: AstraZeneca | Image: Hindustan Times

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post